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Abstract 
Objective: To determine the frequency, associations and outcomes of cerebrovascular 
events (CerVEs) in a multi-ethnic/racial, prospective, SLE disease inception cohort. 
Methods: Patients were assessed annually for 19 neuropsychiatric (NP) events including 
5 types of CerVEs: (i) Stroke; (ii) Transient ischemia; (iii) Chronic multifocal ischemia; (iv) 
Subarachnoid/intracranial hemorrhage; (v) Sinus thrombosis. Global disease activity 
(SLEDAI-2K), SLICC/ACR damage index (SDI) and SF-36 scores were collected. Time to 
event, linear and logistic regressions and multi-state models were used as appropriate. 
Results: Of 1,826 SLE patients, 88.8% were female, 48.8% Caucasian, mean±SD age 
35.1±13.3 years, disease duration 5.6±4.2 months and follow-up 6.6±4.1 years. CerVEs 
were the fourth most frequent NP event: 82/1,826 (4.5%) patients had 109 events, 
103/109 (94.5%) were attributed to SLE and 44/109 (40.4%) were identified at enrollment. 
The predominant events were stroke [60/109 (55.0%)] and transient ischemia [28/109 
(25.7%)]. CerVEs were associated with other NP events attributed to SLE (HR (95% CI): 
(3.16; 1.73-5.75) (p<0.001), non-SLE NP (2.60; 1.49-4.51) (p<0.001), African ancestry at 
US SLICC sites (2.04; 1.01-4.13) (p=0.047) and organ damage (p=0.041). Lupus 
anticoagulant increased the risk of first stroke and sinus thrombosis [2.23 (1.11, 4.45) 
p=.024] and TIA [3.01 (1.15, 7.90) p=0.025]. Physician assessment indicated resolution or 
improvement in the majority but patients reported sustained reduction in SF-36 summary 
and subscale scores following CerVEs (P<0.0001).  
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Conclusion: CerVEs, the fourth most frequent NP event in SLE, are usually attributable to 
lupus. In contrast to good physician reported outcomes, patients report a sustained 
reduction in health-related quality of life following CerVEs. 
(Word count 250/250) 
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Significance and Innovation 
 A large, international, multi-ethnic/racial, disease inception cohort of SLE patients 
was established for the study of clinical outcomes and pathogenic mechanisms of 
nervous system disease. 
 
 In this study we report on the frequency, attribution, clinical and autoantibody 
associations of all cerebrovascular events in 1,826 SLE patients with a mean 
followup pf 6.6 years. 
 
 The most frequent cerebrovascular events were stroke and transient ischemia, the 
majority of which were attributable to SLE rather than atherosclerosis or other 
causes. 
 
 Cerebrovascular events were associated with a significant and sustained reduction 
in patient self-report health related quality of life even when adjusted for potential 
confounders. 
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Neuropsychiatric (NP) events are frequent in patients with systemic lupus erythematosus 
(SLE)1-5. The attribution of individual NP events to SLE and non-SLE causes is 
challenging. Approximately one-third of all NP events are directly attributed to SLE, 
although the attribution rate varies between individual manifestations6. Regardless of 
attribution, NP events are associated with a negative impact on health-related quality of 
life (HRQoL) in both cross-sectional6 and longitudinal7 studies. Thus, improving clinical 
outcomes in SLE patients must include identification, causal attribution and treatment of 
NP events. In the absence of controlled clinical trials, large observational cohort studies 
with careful documentation of NP events and their attribution, treatment and outcomes 
provides insight into this complex aspect of SLE. 
 
Vascular disease, including involvement of the cerebral circulation, is a frequent cause of 
morbidity and mortality in SLE.  Cerebrovascular events (CerVEs) are reported in 5-18% 
of patients in previous cohort studies 2-5,8.  Potential etiologies include procoagulant factors 
due to SLE (e.g. antiphospholipid antibodies, endothelial activation and vasculitis) and 
factors which promote accelerated atherosclerosis (e.g. hypertension, hyperlipidemia and 
SLE itself).  The relative contribution of these factors and the outcome of clinical CerVEs in 
a general lupus population have not been well documented. 
 
In the present study, we determined the frequency, characteristics, clinical and 
autoantibody associations and outcome assessed by physicians and patients of CerVEs in 
a large, multi-ethnic/racial, prospective, inception cohort of SLE patients. 
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 Patients and Methods 
Research study network: The study was conducted by the Systemic Lupus International 
Collaborating Clinics (SLICC)9, a network of 38 investigators in 36 academic medical 
centers in 12 countries. Data were collected per protocol at enrollment and annually, 
submitted to the coordinating centre in Halifax, Nova Scotia, Canada and entered into a 
centralized Access database. Appropriate procedures ensured data quality, management 
and security. The Nova Scotia Health Authority central zone Research Ethics Board, 
Halifax, and each of the participating centers’ institutional research ethics review boards 
approved the study. 
 
Patients: Patients fulfilled the ACR SLE classification criteria for SLE10, the date of which 
was used as the date of diagnosis, and provided written informed consent. Enrollment was 
permitted up to 15 months following the diagnosis. Demographic variables, education and 
medication history were collected. Lupus-related variables included the SLE Disease 
Activity Index 2000 (SLEDAI-2K)11 and SLICC/ACR damage index (SDI)12. Laboratory 
testing included hematological, biochemical and immunological variables required to 
determine SLEDAI-2K and SDI scores.   
 
Neuropsychiatric (NP) events: An enrollment window extended from 6 months prior to 
the diagnosis of SLE up to the actual enrollment date.  NP events were characterized 
within this window using the ACR case definitions for 19 NP syndromes13. These were 
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diagnosed by clinical evaluation supported by investigations, if clinically warranted, as per 
the guidelines. Patients were reviewed annually with a 6-month window around the 
anticipated assessment date. New NP events and the status of previous NP events since 
the last study visit were determined at each assessment.   
The ACR case definitions13 include 5 types of CerVEs: (i) Stroke; (ii) Transient ischemia; 
(iii) Chronic multifocal ischemia; (iv) Subarachnoid and intracranial hemorrhage; (v) Sinus 
thrombosis. Recurring CerVEs and other NP events within the enrollment window or within 
a follow-up assessment period were recorded once. The date of the first episode was 
taken as the onset of the event. 
 
 Attribution of NP events: In keeping with other publications on NP events within the 
SLICC NPSLE inception cohort, the same decision rules were used to determine the 
attribution of all NP events6,14. Factors considered in the decision rules included: (i) 
temporal onset of NP event(s) in relation to the diagnosis of SLE; (ii) concurrent non-SLE 
factor(s), such as potential causes (“exclusions”) or contributing factors (“associations”) for 
each NP syndrome in the glossary for the ACR case definitions of NP events13; and (iii) 
“common” NP events which are frequent in normal population controls as described by 
Ainiala et al 8. These include isolated headaches, anxiety, mild depression (mood 
disorders failing to meet criteria for “major depressive-like episodes”), mild cognitive 
impairment (deficits in less than 3 of the 8 specified cognitive domains) and 
polyneuropathy without electrophysiological confirmation. Two attribution decision rules of 
different stringency (models A and B) were used 6,14.  
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Attribution Model A:  NP events which had their onset within the enrollment window and 
had no “exclusions” or “associations” and were not one of the NP events identified by 
Ainiala 8 were attributed to SLE.  
Attribution Model B: NP events which had their onset within 10 years of the diagnosis of 
SLE and were still present within the enrollment window and had no “exclusions” and were 
not one of the NP events identified by Ainiala 8 were attributed to SLE. 
NP events that fulfilled criteria for model A (most stringent) or for model B (least stringent) 
were attributed to SLE. By definition, all NP events attributed to SLE using model A were 
included in the NP events using model B. Those events which did not fulfill these criteria 
were classified as a non-SLE NP event.  
 
Outcome of CerVEs: A physician generated 7-point Likert scale was completed at each 
follow-up assessment and compared the change in CerVE between onset and follow-up 
(1=patient demise, 2=much worse, 3=worse, 4=no change, 5=improved, 6=much 
improved, 7=resolved)15. A patient generated SF-36 questionnaire was completed at each 
assessment and provided subscale, mental (MCS) and physical (PCS) component 
summary scores15,16, which were not available to physicians at their assessments. 
 
Autoantibodies: Lupus anticoagulant (LAC), IgG anticardiolipin, anti-β2 glycoprotein-I, 
anti-ribosomal P (anti-P) and anti-NR2 glutamate receptor antibodies were measured at 
the Oklahoma Medical Research Foundation, USA 17-20.  
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 Statistical analysis: Cumulative incidence estimation for first and recurrent CerVE used 
the Kaplan-Meier method. Cox regression, with time as age in years, was used to analyze 
time to SLE CerVE (attributed by Model B and stratified with different baseline risks for 
first-ever or recurrent SLE CerVEs). Hazard ratios (HR) and 95% confidence intervals (CI) 
were calculated. Due to sparse data, logistic regression with generalized estimating 
equations (GEE) estimation was used to analyze grouped Likert scale outcomes (≥5 vs. 
≤4) for unresolved SLE CerVEs. Cox regression was also used for analyzing the time to 
resolution as it examines how quickly the CVD events resolved while the analysis of the 
Likert scale outcome examines the probability of being improved (but not resolved) at a 
specific time point. Covariates included sex, age at diagnosis, disease duration (in years), 
race/ethnicity, SLICC sites, education, ACR criteria at enrollment, SLEDAI-2K (without NP 
variables), SDI (without NP variables), antibodies at baseline and follow-up assessments 
(lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein-I, anti-ribosomal P, anti-NR2), 
medication use since last assessment (corticosteroids, antimalarials, 
immunosuppressants, anticoagulants), nephrotic syndrome, and other ongoing NP events. 
For analyses of the physician-assessed outcomes of CerVEs, history of SLE CerVEs, 
CerVE onset in enrollment window, SLE-attribution, and sub-types of CerVEs were also 
examined. For SF-36 scores, visit number, patient status by CerVE and other NP events 
were also included.   Hypothesis testing utilized Wald’s tests (Cox regression analysis) 
and Score tests (GEE analyses). An estimated multi-state model, with states defined by 
Likert scale scores, provided estimated probabilities of being in states at fixed times after a 
SLE CerVE occured. Transitions were restricted to those between adjacent states (change 
in score of 1 or -1) but occurred in continuous time, allowing moves of >1 state between 
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assessments. Resolution was a final (absorbing) state.  Piecewise constant transition 
rates were assumed with rates within 2 years after onset of a SLE CerVE differing from 
rates subsequently. For analyses of longitudinal SF-36 subscale and summary scores, 
linear regression with GEE estimation allowed for correlation of observations within 
patients. 
 
 
Results 
Patients: 1,826 patients were recruited between October 1999-December 2011, from 
centers in the United States (n=539 (29.5%)), Europe (n=477 (26.1%)) Canada (n=418 
(22.9%)), Mexico (n=223 (12.2%)), and Asia (n=169 (9.3%)) (Table 1). The number of 
patient assessments varied from 1 to 18 with a mean follow-up of 6.6±4.1 years and final 
assessment followup in December 2015. 
 
Neuropsychiatric (NP) manifestations: NP events (≥1) occurred in 929/1,826 (50.9%) 
patients and 476/1,826 (26.1%) had ≥ 2 events over the study period. There were 1,844 
unique NP events, encompassing all 19 NP syndromes in the ACR case definitions13. The 
proportion of NP events attributed to SLE varied from 17.7% (attribution model A) to 
31.1% (attribution model B) and occurred in 12.9% (model A) to 20.7% (model B) of 
patients. Of the 1,844 unique NP events, 1,690 (91.6%) involved the central nervous 
system and 154 (8.4%) the peripheral nervous system13. The classification of events into 
diffuse and focal was 1,424 (77.2%) and 420 (22.8%) respectively14. 
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 Cerebrovascular event frequency and characteristics: There were 109 CerVEs in 
82/1,826 (4.5%) patients. Forty-three of the 109 (39.4%) events in 34/82 (41.5%) patients 
were attributed to SLE using model A, and 103/109 (94.5%) events in 79/82 (96.3%) 
patients were attributed to SLE using model B attribution rules. Forty-four of the 109 
(40.4%) CerVEs were identified at the enrollment visit and the remainder over the ensuing 
follow-up. The predominant events were stroke [60/109 (55.0%)] and transient ischemia 
[28/109 (25.7%)] followed by subarachnoid/intracranial hemorrhage [9/109 (8.3%)], 
chronic multifocal ischemia [9/109 (8.3%)] and sinus thrombosis [3/109 (2.8%)]. The 
estimated cumulative incidence of any CerVE and those attributed to SLE (model B 
attribution rule) after 10 years was 5.0% (95%CI=[3.9%, 6.2%]) and 4.9% (95%CI=[3.7%, 
6.0%]) respectively (Figure 1). In patients with a previous SLE attributed CerVE, the 
estimate at 5 years after first CerVE was 11.4% (95%CI=[3.0%, 19.1%]). The incidence 
rate of first SLE CerVE was 5.8/1000 person years and the incidence of recurrence was 
32.7/1000 person years. There were 3 deaths in the CerVE group, 2 attributed to intra-
cranial hemorrhage and 1 to cardiopulmonary arrest. 
 
Clinical and laboratory associations with SLE cerebrovascular events:  After 
excluding one SLE CerVE occurring 2 years before SLE diagnosis, 102 SLE CerVEs were 
used for analysis. As 8 patients had two SLE CerVEs occurring on the same dates, the 
two events for these patients were only counted once in the Cox regression analyses. 
Overall, there were 78 SLE CerVEs available for examining the risk of first-ever SLE 
CerVE and 16 SLE CerVEs available for examining the risk of recurrent SLE CerVE.  
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 Univariate analysis revealed a positive association [HR (95%CI)] between CerVEs 
attributed to SLE and prior SLE CerVEs 4.4 (2.1, 9.0). Stratifying on this factor, other 
positive associations were with shorter disease duration [HR for 5 years after SLE 
diagnosis vs time at SLE diagnosis 0.20 (0.12, 0.33)], African ancestry at US sites [2.0 
(1.03, 3.90)], SDI score without NP variables [1.21 (1.01, 1.45)], non-SLE NP events [1.70 
(1.03, 2.80)] and previous SLE NP events [2.23 (1.32, 3.78)]. Atrial fibrillation was present 
in 2 patients with CerVEs, 1 with a TIA and another with a stroke. 
 
Variables that were significant in the univariate analyses were included in the subsequent 
multivariate analyses. To avoid excluding observations due to missing values in covariates 
(e.g. patients with disease duration < 6 months at enrollment did not have SDI scores 
available), we first fitted a base model that included disease duration, 
race/ethnicity/location and other ongoing NP events. An association with shorter disease 
duration was again found due to the fact that most of the CerVEs occurred within the 
enrollment window.  When an indicator variable representing the enrolment window was 
introduced into the model, disease duration had no demonstrable effect. The results of 
multivariate regressions examining the associations with CerVEs attributed to SLE using 
the base model are summarized in Table 2. There was a greater risk of a CerVE attributed 
to SLE in patients with concurrent NP events attributed to SLE [aseptic meningitis (1), 
mononeuropathy (1), movement disorder (1), polyneuropathy (1), seizures (4), acute 
confusion (1), cognitive dysfunction (2), mood disorder (6) and psychosis (1), p<0.001)], 
concurrent non-SLE NP events [headache (18), movement disorder (1), plexopathy (1), 
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polyneuropathy (7), acute confusion (1), anxiety (5), cognitive dysfunction (2) and mood 
disorder (5), p<0.001)], and African ancestry at US sites (p=0.047). Note that the prior and 
recurrent SLE CerVE events are allowed to have different baseline hazards (strata), 
therefore the effect of prior SLE CerVE on the risk of SLE CerVE is not presented as a 
hazard ratio in Table 2.  We further examined the associations of SDI scores, medications 
and autoantibodies in addition to the base model and found that increased cumulative 
organ damage scores (excluding NP variables) were positively associated with the risk of 
SLE CerVE (p=0.041). There was no evidence of significant associations of SLE CerVEs 
with medications and autoantibodies (treated as time-varying variables) after adjusting for 
the variables in the base model. 
 
Additional analyses examined specific associations between CerVEs attributed to SLE and 
baseline antiphospholipid antibodies using data on 69 SLE CerVEs with available 
autoantibody data. There was a positive, albeit borderline statistically significant, 
association between LAC at enrolment and risk of first SLE CerVE [1.77 (0.99, 3.16) 
p=0.054)]; the association between baseline LAC and recurrent SLE CVD was also 
positive but not significant [HR=1.7 (0.29, 9.88), global test for interaction p=0.968]. This 
was likely due to the small number of events and the greater use of anticoagulants 
following the initial CerVE (any anticoagulant 12/13 (92%), warfarin 5/13 (39%)) compared 
to at the time of the initial events [any anticoagulant 19/56 (68%), warfarin 4/56 (7%)]. A 
similar analysis restricted to stroke and sinus thrombosis, also demonstrated a relationship 
between LAC at enrolment and the first 36 events [2.23 (1.11, 4.45) p=.024] but was 
insignificant for the 7 subsequent events [2.21 (0.13, 36.9) p=0.58]. When the analysis 
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was restricted to TIAs, a relationship was found for the 18 first events [3.01 (1.15, 7.90) 
p=0.025] but there was insufficient data to examine associations with the 2 subsequent 
TIAs. There was no association with other autoantibodies. 
 
Clinical outcome of cerebrovascular events: Excluding TIAs there were 74 SLE 
CerVEs available for time to resolution analysis. Of these, 47 (63.5%) were resolved by 
the end of study (36 strokes, 5 chronic multifocal disease, 4 subarachnoid and intracranial 
hemorrhage, and 2 sinus thrombosis). Figure 2a illustrates the probability of CerVEs 
(excluding TIAs) not resolving over time. For stroke the estimated probability at 10 years 
was 11.6% [95% CI [3.6%, 37.3%)); for chronic multifocal disease/subarachnoid and 
intracranial hemorrhage/sinus thrombosis it was 19.8% ([4.28%, 91.5%]) and for the total 
group it was 11.64% ([3.85%, 35.2%]). Overall there were no predictors found to be 
associated with resolution of CerVE.  
 
Figure 2b summarizes the distribution of maximum and minimum Likert scale scores 
indicating physician assessment of outcome of CerVEs during follow-up. Two of the three 
patients who died had a total of three preceding CerVEs shortly prior to death and thus 
had both maximum and minimum Likert scores of 1 (patient demise).  The third patient 
who died had a CerVE which improved over several years prior to death. For this patient 
the minimum and maximum scores were 1 (patient demise) and 6 (much improved) 
respectively. The estimated percentages, from a multi-state model of living patients with 
individual Likert scores between 2 and 7, at 5 years after the onset of a CerVE, were 
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0.5%, 0.6%, 10.8%, 11.3%, 5.8%, 71% respectively. The estimated percentages after 10 
years were 0.5%, 0.4%, 7.2%, 6.9%, 3.4%, 81.7%, respectively. Greater improvement in 
unresolved CerVEs was associated with CerVEs attributed to SLE (model A) (p= 0.005) 
and younger age (p=0.02) in univariate logistic regression analyses for grouped Likert 
scores, after adjusting for time since CerVE onset. Similar findings were observed in the 
multivariate analyses.  
 
Cerebrovascular events and Health-Related Quality of Life: The association between 
CerVEs and SF-36 summary and sub-scale scores is illustrated in Figures 3 and 4 using 
data in three groups of patients over time: (i) SLE CerVEs (single or multiple, including 
TIAs) which occurred at or prior to the study assessment; (ii) any NP event other than an 
SLE CerVE occurring at or prior to the study assessment; (iii) patients who never had any 
NP event up to the study assessment. Once assigned, each patient retained the same 
group membership throughout the study unless they had a new or subsequent NP event 
which could trigger a change in group assignment.  The lowest mean (SD) PCS score 
occurred in patients with SLE CerVEs [37.3 (11.5)] compared to patients with other NP 
events [40.7 (11.8)] and patients without NP events [43.9 (11.0)] [overall p<0.0001 after 
adjusting for time/visit, sex, age at SLE diagnosis, race/ethnicity/location, education, 
SLEDAI-2K and SDI (without NP variables) scores, corticosteroids, antimalarials and 
immunosuppressant use since last assessment].  Similar but less marked differences in 
mean (SD) MCS scores were seen with the same group assignment [43.1 (12.5) vs 45.1 
(12.2) vs 48.8 (10.8)] (overall p<0.0001 after adjustments) (Figure 3A). For both PCS and 
MCS scores there were significant differences between groups (i) and (iii) (p=0.0034 and 
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p<0.0001, respectively) but not between groups (i) and (ii) (p>0.05). The mean group 
differences in individual SF-36 subscale scores in the same three groups of patients 
(Figure 3B), indicated that all eight self-reported health domains were lowest in patients 
with SLE CerVEs compared to the other two groups. Finally, the group differences in PCS 
and MCS scores over time (Figure 4) persisted for 10 years of follow-up (global p-values 
for group effects <0.0001 after adjustments although there was some evidence for small 
numerical variation in the PCS group differences over time (global p-value for linear 
interaction terms of time and NP groups = 0.01) with none for the MCS group differences 
over time. 
 
Multivariate analysis for adjustment variables also identified a number of factors 
[regression coefficient (95%CI)] associated with SF-36 summary scores (data not shown). 
Female sex [-3.12 (-4.54, -1.70), P<.0001], older age at SLE diagnosis [-0.20 (-0.24, -
0.17), P<.0001], Caucasians at US sites [-3.52 (-5.22, -1.83)] and African ancestry at non-
US sites  [-2.26 (-4.05, -0.47) global p<.0001], higher SLEDAI-2K [-1.03 (-1.28, -0.78) 
p<.0001] and SDI scores computed without NP variables [SDI 4+ vs. 0= -4.08 (-5.93, -
2.23) global p<.0001], and corticosteroid use [-2.04 (-2.64, -1.43) p<.0001] were 
associated with lower PCS scores. Conversely, patients with Asian [3.44 (2.21, 4.67) and 
Hispanic race/ethnicity [3.46 (2.12, 4.81), global p for race/ethnicity effect <.0001] and 
post-secondary education [1.86 (0.93, 2.79) p<.0001] had higher PCS scores.  For MCS, 
female sex [-1.57 (-3.09, -0.05) p=0.043], higher SLEDAI-2K scores [-0.57 (-0.87, -0.26), 
p=0.0003] and corticosteroid use [-0.89 (-1.54, 0.23) p=0.0085) were associated with 
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lower scores. Conversely, patients with Asian race/ethnicity had higher MCS scores [2.35 
(1.06, 3.64) global p for race/ethnicity effect=0.008]. 
 
Discussion 
Although vascular NP events are not the most frequent of neurological presentations in 
SLE patients, they are one of the more serious. CerVEs are not included in the revised 
ACR classification criteria for SLE10 (seizures and psychosis) or in the more recent SLICC 
classification criteria which has six NP manifestations21.  A meta-analysis involving 5,057 
SLE patients using ACR case definitions for CerVEs, found an overall prevalence of 5% 
(3.6%-7.2%)22. In our study, CerVEs were ranked the fourth most common NP event with 
a prevalence of 4.5%. The most frequent types of CerVEs were strokes and TIAs and the 
majority, regardless of type, was attributed to SLE (96.3% of CerVEs using attribution 
model B) and associated with LAC.  The attribution to SLE was higher than for more 
frequent NP events in the SLICC cohort such as isolated headache (0%)23, mood 
disorders (38.3%)24 and seizures (85.7%)25.  Although risk factors for atherosclerosis have 
been reported in the cohort26, these was not causally related to CerVEs. As most of the 
events occurred early in the disease course, it is possible that CerVEs occurring later in 
the disease may be more frequently attributed to atherosclerosis but further follow-up is 
required to confirm this. 
 
In addition to the association with LAC, CerVEs were associated with clinical variables. In 
particular, the occurrence of a prior event was predictive of a subsequent event with a five-
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fold increase. As reported with other NP events23-25, CerVEs in SLE patients frequently do 
not occur in isolation but rather in association with concurrent NP events attributed to both 
SLE and non-SLE causes. The association with increased organ damage, which has been 
reported previously27, underlines the link of NPSLE with serious events in other organ 
systems either attributed to SLE itself, complications of therapy or comorbid factors. 
Finally, the association between CerVEs and patients of African ancestry at US SLICC 
sites suggests contributions from both genetic and environmental factors. 
 
Few studies describe the clinical outcome of stroke in SLE28-30 , frequently utilizing health 
administrative data on hospitalized patients29,30. In these studies, the functional outcome 
was comparable to the general population28-30 and better than in patients with rheumatoid 
arthritis29, although both comparator populations were older. In the current study, 
physician assessment of outcome following CerVEs was generally favourable. In contrast, 
the assessment of health status by patients with CerVEs, as reflected by both summary 
and subscale scores of the SF-36, indicated a significant and sustained reduction in 
HRQoL. Although TIAs were not included in physician assessment of outcome, they were 
included in health status scores, further highlighting the difference in assessment of 
outcomes between physicians and patients. Discordance of health concerns between 
patients and physicians has been demonstrated in a recent study of SLE patients 31. 
Specifically, the predominant concerns of patients were function and fatigue, whereas 
physicians focused on SLE-related factors. A systemic review of qualitative research 
studies in SLE 32 has emphasized the significant psychological impact of the disease 
which can be addressed in part through participation in self-management programs 33.  
23 
 
 There are some limitations to the current study. First, the absence of a control population 
precludes more definitive interpretation of the frequency of CerVEs in SLE patients. This 
was not feasible and is compensated by the size of the inception cohort, the prospective 
study design and standardized data collection.  Second, specialized investigations such as 
neuroimaging were not routinely performed but left to the discretion of individual 
investigators. Likely, the universal application of such investigations would have detected 
additional intra-cranial abnormalities but our protocol more accurately reflects what is done 
in clinical practice. Third, the unavailability of autoantibody data for some patients may 
have limited our ability to fully assess their association with CerVEs. Fourth, the potential 
contribution of accelerated atherosclerosis to CerVEs could not be fully evaluated and 
longer term follow-up is required. Finally, missing data due to loss to follow-up or death is 
an inevitable limitation of observational cohort studies but our results are relevant to the 
patient population that was alive and still under follow-up.  If there was a large amount of 
missing covariate data (e.g. SDI scores), the analyses were performed with and without 
covariates. When autoantibodies were unavailable over follow-up assessments, we 
applied the ‘last observation carry forward’ imputation.  
 
Despite these limitations, the results emphasize many salient features of CerVEs in SLE. 
This includes their predilection for presenting early in the disease course, their association 
with clinical and serological variables and their short and long-term impact on HRQoL.   
(Word count 3,788) 
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Table 1: Demographic and clinical manifestations of SLE patients at enrolment.  
Number of Patients 1826 
Gender (%) Female  
Male 
1622 (88.8) 
204 (11.2) 
Age (years) (mean ± SD) 35.1 ± 13.3 
Race/Ethnicity (%) Caucasian                                        
African ancestry                                                   
Asian                                                                                                                                                             
Hispanic 
Other  
891 (48.8) 
306 (16.8) 
275 (15.1)
282 (15.4) 
72 (3.9) 
Single/Married/Other (%)  818 (44.9)/767 (42.1)/237 (13.0) 
Post secondary education (%) 1064 (61.9) 
Disease duration (months) (mean ± SD) 5.6 ± 4.2 
Number of ACR criteria (mean ± SD) 4.9 ± 1.1 
ACR manifestations (%)  
 Malar rash 
Discoid rash 
Photosensitivity 
Oral/nasal ulcers 
Serositis 
Arthritis 
Renal disorder 
Neurological disorder 
Hematologic disorder 
Immunologic disorder 
Antinuclear antibody 
660 (36.1) 
227 (12.4) 
652 (35.7) 
677 (37.1) 
502 (27.5) 
1368 (74.9) 
510 (27.9) 
88 (4.8) 
1129 (61.8) 
1392 (76.2) 
1731 (94.8) 
SLEDAI-2K score (mean ± SD) 5.3  ±  5.4 
*SLICC/ACR damage index score (mean ± SD) 0.31 ± 0.73 
Medications (%) Corticosteroids 
Antimalarials 
Immunosuppressants 
ASA 
Antidepressants 
Warfarin 
Anticonvulsants 
Antipsychotics 
 
1284 (70.3) 
1231 (67.4) 
732 (40.1) 
256 (14.0) 
183 (10.0) 
96 (5.3) 
80 (4.4) 
12 (0.7) 
 
Autoantibodies (%) 
 
Lupus anticoagulant 
 
241/1174 (20.5) 
 Anticardiolipin 138/1142 (12.1) 
 Anti-β2 glycoprotein-I 163/1142 (14.3) 
 Anti-ribosomal P 112/1136 (9.9) 
 Anti-NR2  130/1064 (12.2) 
   
Smoking (%)  270/1824 (14.8) 
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Hypertension (%)  627/1823 (34.4) 
Diabetes (%)  67/1808 (3.7) 
Obese (%)  548/1752 (31.3) 
Hypercholesterolemia (%)  648/1824 (35.5) 
Family history of CAD (%)  427/1826 (23.4) 
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Table 2: Multivariate regression analysis for predictors of cerebrovascular 
                    events attributed to SLE (model B).  
Variable  
Hazard 
Ratio 
Hazard 
Ratio 
(lower 
95% CI) 
Hazard 
Ratio 
(upper 
95% CI) 
P-value 
(Wald) 
Other ongoing 
NP events(ref: 
No NP events)  
 
Any SLE NP 
events ongoing 
3.16 1.73 5.75 <.001 
All non-SLE NP 
events ongoing 
2.60 1.49 4.51 <.001 
overall (Wald) . . . <.001 
Enrollment 
window 
Yes 6.08 3.18 11.64 <.001 
Sex Female 0.70 0.41 1.21 0.200 
Disease 
duration (years) 
 0.94 0.85 1.04 0.201 
Race/Ethnicity/l
ocation (ref: 
EU/CAN 
Caucasian) 
 
Asian 0.67 0.28 1.62 0.376 
Hispanic 1.29 0.67 2.48 0.454 
Other African 1.43 0.64 3.19 0.381 
US African 2.04 1.01 4.13 0.047 
US Caucasian 0.95 0.46 1.97 0.899 
other 1.04 0.34 3.16 0.943 
Global (Wald) test . . . 0.337 
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Figure 1: The estimated cumulative incidence of initial (A) and recurrent (B) 
cerebrovascular events (CerVE).  Events were attributed to SLE using attribution model B. 
A 
 
B 
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Figure 2: Physician determined change in cerebrovascular events (CerVE) attributed to 
SLE (model B).  A: Survival curves for resolution. B: The highest and lowest Likert scale 
scores over the duration of followup are shifted to the right indicated improvement. 
                
 A 
  
B 
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Figure 3: Association of SF-36 summary and subscale scores with cerebrovascular 
events (CerVE) attributed to SLE using attribution model B. 
 
A: mean (SD) physical component summary (PCS) and mental component summary 
(MCS) scores in the 3 patient groups. The number of assessments contributing to each 
bar are aggregated for patients over time. Thus one patient can contribute to both groups 
if her/his CerVE/NP status changed over time.  
 B: comparison individual subscale scores in the 3 patient groups. The SF-36 subscales 
are VT = Vitality, SF = Social function, RE = Role emotion, MH = Mental health, PF = 
Physical function, RP = Role physical, BP = Bodily pain, GH= General health. 
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Figure 4: SF-36 physical component summary (PCS) and mental component summary 
(MCS) scores with cerebrovascular events (CerVE) over time. Events were attributed to 
SLE using attribution model B. 
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